Rice Hall James & Associates LLC Invests $18.63 Million in QuidelOrtho Corporation $QDEL

Rice Hall James & Associates LLC bought a new stake in QuidelOrtho Corporation (NASDAQ:QDEL) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,063,559 shares of the company’s stock, valued at approximately $18,628,000. Rice Hall James & Associates LLC owned approximately 1.56% of QuidelOrtho as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Edgestream Partners L.P. acquired a new position in QuidelOrtho during the 1st quarter worth approximately $1,937,000. Tejara Capital Ltd boosted its stake in shares of QuidelOrtho by 97.2% in the fourth quarter. Tejara Capital Ltd now owns 208,327 shares of the company’s stock valued at $5,950,000 after buying an additional 102,700 shares in the last quarter. Segall Bryant & Hamill LLC boosted its stake in shares of QuidelOrtho by 29.2% in the first quarter. Segall Bryant & Hamill LLC now owns 1,543,410 shares of the company’s stock valued at $25,358,000 after buying an additional 348,549 shares in the last quarter. Paradigm Capital Management Inc. NY grew its holdings in QuidelOrtho by 84.1% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,525,900 shares of the company’s stock worth $25,071,000 after acquiring an additional 697,010 shares during the period. Finally, Gagnon Securities LLC grew its holdings in QuidelOrtho by 29.9% during the fourth quarter. Gagnon Securities LLC now owns 159,177 shares of the company’s stock worth $4,546,000 after acquiring an additional 36,678 shares during the period. 99.00% of the stock is owned by hedge funds and other institutional investors.

QuidelOrtho Price Performance

QuidelOrtho stock opened at $14.58 on Tuesday. The firm has a market capitalization of $999.75 million, a PE ratio of -0.95 and a beta of 0.68. QuidelOrtho Corporation has a 52 week low of $9.92 and a 52 week high of $35.58. The firm’s 50-day simple moving average is $15.80 and its 200 day simple moving average is $16.80. The company has a quick ratio of 0.76, a current ratio of 1.39 and a debt-to-equity ratio of 1.43.

QuidelOrtho (NASDAQ:QDEL) last announced its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The company had revenue of $630.90 million during the quarter, compared to analysts’ expectations of $618.72 million. During the same quarter in the previous year, the business posted $0.12 earnings per share. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, equities research analysts predict that QuidelOrtho Corporation will post 0.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

QDEL has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research note on Friday, July 17th. JPMorgan Chase & Co. raised their price objective on shares of QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research note on Wednesday, July 1st. Wall Street Zen raised shares of QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Zacks Research downgraded shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 12th. Finally, Citigroup boosted their price target on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Three equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $13.62.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.